Health Catalyst Q3 revenue falls 26% to $56.3 million; reaffirms 2026 outlook
Health Catalyst reported third-quarter 2026 revenue of $56.3 million, down 26% from $76.3 million a year earlier, and Adjusted EBITDA of $779 thousand, versus $12.0 million. GAAP net income was $40.5 million, compared with a $22.2 million loss, largely because of a $65.9 million gain on the sale of its Vitalware business, which closed on July 31, 2026. The company reaffirmed its full-year 2026 guidance of $246 million to $249 million in revenue and $18 million to $18.5 million in Adjusted EBITDA.
Key points
- Q3 2026 revenue was $56.3 million, down from $76.3 million; gross margin was 31%, down from 39%.
- GAAP net income was $40.5 million, or $0.53 per diluted share, versus a net loss of $22.2 million; the result includes a $65.9 million gain on the Vitalware sale.
- Adjusted EBITDA was $779 thousand, down from $12.0 million a year earlier.
- Full-year 2026 guidance was reaffirmed: total revenue of $246 million to $249 million and Adjusted EBITDA of $18 million to $18.5 million.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.